Therapeutic Targets In Breast Cancer Signaling: A Review

被引:17
作者
Obeagu, Emmanuel Ifeanyi [1 ]
Babar, Quratulain [2 ]
Vincent, C. C. N. [3 ]
Udenze, Chikwendu Lawrence [4 ]
Eze, Richard [5 ]
Okafor, Chukwuma J. [6 ]
Ifionu, Bart I. [7 ]
Amaeze, Augustine Amaeze [8 ]
Amaeze, Florence Ngozi [9 ]
机构
[1] Imo State Univ, Dept Med Lab Sci, Owerri, Imo State, Nigeria
[2] Govt Coll Univ, Dept Biochem, Faisalabad, Pakistan
[3] Imo State Univ, Dept Nursing Sci, Owerri, Imo State, Nigeria
[4] Michael Okpara Univ Agr, Dept Univ Hlth Serv, Umudike, Abia State, Nigeria
[5] Madonna Univ Elele, Dept Med Lab Sci, Elele, Rivers State, Nigeria
[6] State Univ Zanzibar, Dept Pathol & Biochem, Zanzibar, Tanzania
[7] Olabisi Onabanjo Univ, Dept Chem Pathol & Immunol, Ogun State, Nigeria
[8] Evangel Univ, Dept Physiotherapy, Akaeze, Ebonyi State, Nigeria
[9] Gregory Univ, Dept Publ Hlth Educ, Uturu, Abia State, Nigeria
关键词
Breast cancer; tumor; apoptosis; cell proliferation; AMERICAN SOCIETY; JAK/STAT PATHWAY; IN-VIVO; PROMOTES; ACTIVATION; CELLS; TUMOR; PROLIFERATION; PROGESTERONE; SUPPRESSES;
D O I
10.9734/JPRI/2021/v33i56A33889
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
For women, the most dominant type of cancer is breast cancer and perhaps one of the most recognizedreasons of death. This is a disorder of many distinct traits, many of which are known as positive hormone receptor, human epidermal receptor-2 (HER2+), and three negative breast cancers (TNBC). Drugs that directly target and kill tumors constitute a rapidly-growing form of molecular therapy for cancer patients. Analysis reveals that stable breast tissue cells exhibit receptors which aren't usually present. As a result, it is imperative to cognize the molecular roots of breast cancer and the myriad compromised pathology-related processes and pathways to ensure progresses in early diagnosis and prevention. This study demonstrates essential cellular pathways relevant for breast cancer including improvements in cell proliferation, apoptosis, and hormone balances in breast tissues. On the basis of these notions, we consider how breast cancer is associated to the creation of potentially therapeutic interventions and predictive biomarkers.
引用
收藏
页码:82 / 99
页数:18
相关论文
共 138 条
[101]   Signal Transduction in Cancer [J].
Sever, Richard ;
Brugge, Joan S. .
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE, 2015, 5 (04)
[102]   Targeting the JAK/STAT Signaling Pathway for Breast Cancer [J].
Shao, Fei ;
Pang, Xiaonan ;
Baeg, Gyeong Hun .
CURRENT MEDICINAL CHEMISTRY, 2021, 28 (25) :5137-5151
[103]   Keratin 19 regulates cell cycle pathway and sensitivity of breast cancer cells to CDK inhibitors [J].
Sharma, Pooja ;
Alsharif, Sarah ;
Bursch, Karina ;
Parvathaneni, Swetha ;
Anastasakis, Dimitrios G. ;
Chahine, Joeffrey ;
Fallatah, Arwa ;
Nicolas, Kevin ;
Sharma, Sudha ;
Hafner, Markus ;
Kallakury, Bhaskar ;
Chung, Byung Min .
SCIENTIFIC REPORTS, 2019, 9
[104]   Epigenetic and breast cancer therapy: Promising diagnostic and therapeutic applications [J].
Sher, Gulab ;
Salman, Nadia Aziz ;
Khan, Abdul Q. ;
Prabhu, Kirti S. ;
Raza, Afsheen ;
Kulinski, Michal ;
Dermime, Said ;
Haris, Mohammad ;
Junejo, Kulsoom ;
Uddin, Shahab .
SEMINARS IN CANCER BIOLOGY, 2022, 83 :152-165
[105]   Low Dose of Paclitaxel Combined with XAV939 Attenuates Metastasis, Angiogenesis and Growth in Breast Cancer by Suppressing Wnt Signaling [J].
Shetti, Dattatrya ;
Zhang, Bao ;
Fan, Conghui ;
Mo, Canlong ;
Lee, Bae Hoon ;
Wei, Kun .
CELLS, 2019, 8 (08)
[106]  
Song HM, 2019, EXP MOL MED, V51
[107]   EGFR Promotes the Development of Triple Negative Breast Cancer Through JAK/STAT3 Signaling [J].
Song, Xiang ;
Liu, Zhaoyun ;
Yu, Zhiyong .
CANCER MANAGEMENT AND RESEARCH, 2020, 12 :703-717
[108]   circHMCU Promotes Proliferation and Metastasis of Breast Cancer by Sponging the let-7 Family [J].
Song, Xiaojin ;
Liang, Yiran ;
Sang, Yuting ;
Li, Yaming ;
Zhang, Hanwen ;
Chen, Bing ;
Du, Lutao ;
Liu, Ying ;
Wang, Lijuan ;
Zhao, Wenjing ;
Ma, Tingting ;
Wang, Chuanxin ;
Yang, Qifeng .
MOLECULAR THERAPY-NUCLEIC ACIDS, 2020, 20 :518-533
[109]   CDK 4/6 Inhibitors in Breast Cancer: Current Controversies and Future Directions [J].
Spring, Laura M. ;
Wander, Seth A. ;
Zangardi, Mark ;
Bardia, Aditya .
CURRENT ONCOLOGY REPORTS, 2019, 21 (03)
[110]   Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer [J].
Stover, Daniel G. ;
Del Alcazar, Carlos R. Gil ;
Brock, Jane ;
Guo, Hao ;
Overmoyer, Beth ;
Balko, Justin ;
Xu, Qiong ;
Bardia, Aditya ;
Tolaney, Sara M. ;
Gelman, Rebecca ;
Lloyd, Maxwell ;
Wang, Yu ;
Xu, Yaomin ;
Michor, Franziska ;
Wang, Vivian ;
Winer, Eric P. ;
Polyak, Kornelia ;
Lin, Nancy U. .
NPJ BREAST CANCER, 2018, 4